Upfront admixing antibodies and EGFR inhibitors preempts sequential treatments in lung cancer models

Some antibacterial therapies entail sequential treatments with different antibiotics, but whether this approach is optimal for anti‐cancer tyrosine kinase inhibitors (TKIs) remains open. EGFR mutations identify lung cancer patients who can derive benefit from TKIs, but most patients develop resistan...

Descripción completa

Detalles Bibliográficos
Autores principales: Marrocco, Ilaria, Romaniello, Donatella, Vaknin, Itay, Drago‐Garcia, Diana, Oren, Roni, Uribe, Mary Luz, Belugali Nataraj, Nishanth, Ghosh, Soma, Eilam, Raya, Salame, Tomer‐Meir, Lindzen, Moshit, Yarden, Yosef
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8033519/
https://www.ncbi.nlm.nih.gov/pubmed/33660397
http://dx.doi.org/10.15252/emmm.202013144

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8033519/
https://www.ncbi.nlm.nih.gov/pubmed/33660397
http://dx.doi.org/10.15252/emmm.202013144

Ejemplares similares